40 results
8-K
EX-99.1
CADL
Candel Therapeutics, Inc.
23 May 24
Regulation FD Disclosure
5:05pm
conducted under a Special Protocol Assessment with the FDA. The FDA has also granted Orphan Drug Designation to CAN-2409 for the treatment of PDAC.
About
8-K
EX-99.1
CADL
Candel Therapeutics, Inc.
25 Apr 24
Candel Therapeutics Announces Upcoming Presentations
8:30am
phase 3 clinical trial in prostate cancer is being conducted under a Special Protocol Assessment by FDA. The FDA has also granted Orphan Drug Designation
8-K
EX-99.1
g7z7sgvv czn434y
11 Apr 24
Candel Therapeutics Receives FDA Orphan Drug Designation for CAN-2409 for the Treatment of Pancreatic Cancer
9:00am
8-K
EX-99.1
l95fixky re
4 Apr 24
Candel Therapeutics Announces Positive Interim Data from Randomized Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer
8:30am
8-K
EX-99.1
kbshmt027qkro0
12 Dec 23
Candel Therapeutics Receives FDA Fast Track Designation for CAN‑2409 in Pancreatic Cancer
8:30am
8-K
EX-99.1
z7amy is80
19 May 23
Regulation FD Disclosure
9:15am
8-K
EX-99.1
q5svq
6 Dec 22
Regulation FD Disclosure
8:01am